BioSpace News Archive

Medtronic plc announced financial results for its first quarter of fiscal year 2021, which ended July 31, 2020.

Imara Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, announced that the European Commission granted Orphan Drug designation to IMR-687 for the treatment of patients with sickle cell disease.

POINT Biopharma Inc. is announcing the appointment of key members to its leadership team — Jessica Jensen as Executive Vice President of Clinical Development, Valerie Hergott as Senior Director of Chemistry, Manufacturing and Controls and Bill Demers as Chief Financial Officer.

Antigen-specific CD4+ and CD8+ T cell responses in the lung not previously shown with advanced COVID-19 vaccine candidates

Mereo BioPharma Group plc, “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announced the initiation of a Phase 1b/2 placebo-controlled clinical trial to evaluate the safety and efficacy of alvelestat in hospitalized, adult patients with moderate to severe COVID-19 respiratory disease.

Yuva Biosciences, an anti-aging startup based on technology developed by one of the world leaders in mitochondrial sciences, Dr. Keshav K. Singh, announced that Dr. Singh has published an article, “Decoding SARS-CoV-2 Hijacking the Host Mitochondria in Pathogenesis of COVID-19" in the American Journal of Physiology.

Acquisitions of MVE, along with CRYOPDP is expected to increase Cryoport’s revenue run rate to over $160 million and to be immediately accretive

Sutro Biopharma, Inc. announced that it has achieved a clinical supply milestone under its collaboration and license agreement with the healthcare division of Merck KGaA, Darmstadt, Germany and is entitled to receive a milestone payment.

Company expects to initiate enrollment in the Phase II trial, ALTITUDE, in the second half of 2020 to evaluate the targeted, in-office suprachoroidal delivery of RGX-314

Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid technology, announced that it will host a virtual KOL meeting on Wednesday, September 16th, 2020 from 10:30 am-12 pm ET to discuss the preliminary Phase 1b efficacy and safety data for cavrotolimod, Exicure’s SNA-enabled TLR9 agonist for solid tumors.